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Abstract
Adipocyte enhancer binding protein 1 (AEBP1) is a multifunctional protein that negatively regulates the tumor suppressor
PTEN and IkBa, the inhibitor of NF-kB, through protein-protein interaction, thereby promoting cell survival and
inflammation. Mice homozygous for a disrupted AEBP1 gene developed to term but showed defects in growth after birth.
AEBP1
2/2 females display lactation defect, which results in the death of 100% of the litters nursed by AEBP1
2/2 dams.
Mammary gland development during pregnancy appears normal in AEBP1
2/2 dams; however these mice exhibit expansion
of the luminal space and the appearance of large cytoplasmic lipid droplets (CLDs) in the mammary epithelial cells at late
pregnancy and parturition, which is a clear sign of failed secretory activation, and accumulation of milk proteins in the
mammary gland, presumably reflecting milk stasis following failed secretory activation. Eventually, AEBP1
2/2 mammary
gland rapidly undergoes involution at postpartum. Stromal restoration of AEBP1 expression by transplanting wild-type bone
marrow (BM) cells is sufficient to rescue the mammary gland defect. Our studies suggest that AEBP1 is critical in the
maintenance of normal tissue architecture and function of the mammary gland tissue and controls stromal-epithelial
crosstalk in mammary gland development.
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Introduction
The mammary gland is a self-renewing tissue in which
morphological changes and differentiation occur cyclically during
menstruation, pregnancy and lactation. In prepubescent mice, the
gland consists of a small ductal tree that emanates from the nipple
into the proximal part of the fatty stroma, the mammary fat pad.
Upon initiation of ovarian hormone secretion, the mammary
epithelium enters an accelerated growth phase that leads to
extension and branching of the ducts until they reach the limits of
the fat pad. At the onset of pregnancy, extensive epithelial cell
proliferation occurs, leading to the formation of lobulo-alveolar
structures and secretory epithelial differentiation for lactation. At
parturition, a dramatic increase in the expression of milk proteins
and lipid biosynthetic enzymes has been observed [1,2]. The
transition from late pregnancy to lactation is stimulated by a rise in
prolactin and decrease in serum progesterone [3], and this
transition is referred to as secretory activation [4,5]. The event
of involution that follows weaning results in the quenching of milk
protein gene expression, collapse of the alveolar structures,
removal of endothelial, myoepithelial and secretory luminal
epithelial cells by apoptosis, phagocytosis by macrophages,
proteolytic degradation of the basement membranes, and
replacement of most epithelial cells by adipose tissue [6].
Adipocyte enhancer-binding protein 1 (AEBP1) is a transcrip-
tional repressor that was initially shown to be involved in
adipocyte differentiation [7]. Further study revealed that direct
binding of the c5 subunit of a heterotrimeric G protein with
AEBP1 could regulate this transcriptional repression [8]. Aortic
carboxypeptidase-like protein (ACLP) is an N-terminally extended,
non-nuclear isoform of AEBP1 that contains a signal peptide and a
lysine- and proline-rich 11-amino acids repeating motif [9], which
are absent in AEBP1. Western blot analysis showed that ACLP is
predominantly expressed in the smooth muscle cells of the adult
mouse aorta but not in the adventitia, heart, liver, skeletal muscle,
or kidney, while in situ hybridization experiments showed that
ACLP is expressed in the smooth muscle cells of the aorta, but not
in skeletal muscle cells [9]. In contrast, AEBP1 expression is
detected in various tissues [10]. ACLP expression is up-regulated
during vascular smooth muscle cell differentiation [9], whereas
AEBP1 expression is down-regulated during adipocyte differenti-
ation [7]. AEBP1 gene contains 21 exons spanning over 10 kb of
genomic DNA. This gene gives rise to AEBP1 and ACLP mRNAs
by alternative splicing [10].
AEBP1 has been found to interact with mitogen-activated
protein kinase (MAPK) [11], suggesting an involvement in the
signaling cascade directing extracellular signals to the nucleus. We
have shown that MAPK regulates the transcriptional activity of
AEBP1 by a novel dual mechanism, in which MAPK interaction
enhances and subsequent phosphorylation decreases the DNA-
binding ability of AEBP1 [12]. Using the yeast two-hybrid system,
AEBP1 was also previously identified as an interacting partner of
the tumor suppressor PTEN (phosphatase and tensin homolog
deleted in chromosome ten) [13]. We have shown that AEBP1
physically interacts with PTEN in mammalian cells and this
interaction promotes PTEN degradation [14]. Studies with
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TG) mice, which over-express AEBP1
transgene in the adipose tissues and macrophages [14], and
AEBP1
2/2 mice [15] suggested that AEBP1 plays a key functional
role in in vivo modulation of adiposity through its negative
regulation of PTEN. PTEN has also been shown to play an
important role in mammary gland development and tumorigenesis
[16,17].
AEBP1 is also a pivotal player in macrophage cholesterol
homeostasis and macrophage inflammatory responsiveness; key
events involved in atherogenesis [18,19]. AEBP1 impedes
macrophage cholesterol efflux and promotes foam cell formation
via PPARc1 and LXRa down-regulation, which is accompanied
by concurrent repression of major cholesterol efflux mediators,
leading to foam cell formation [20]. AEBP1 was shown to promote
macrophage inflammatory responsiveness by inducing NF-kB
activity through hampering IkBa inhibitory function via protein-
protein interaction [21]. We further showed that LPS-induced
down-regulation of pivotal macrophage cholesterol efflux media-
tors, leading to foam cell formation, is largely mediated by AEBP1,
and this regulatory role of AEBP1 is physiologically relevant given
that AEBP1 ablation attenuates LPS-induced foam cell formation
[22]. Finally, our recent in vivo data clearly demonstrated that
macrophage AEBP1 plays critical regulatory roles in atherogenesis
[23].
In this study, we explore the physiological role of AEBP1 in the
lactation defect observed in AEBP1-null mice. Our results
highlight the role that AEBP1 plays in signaling physiological
maintenance of normal tissue architecture and function of the
mammary gland tissue. BM transplantation experiments reveal
that stromal expression of AEBP1 is required for normal
mammary gland development. Our results presented here show
that AEBP1 is a critical stromal factor that mediates stromal-
epithelial crosstalk in the regulation of mammary gland develop-
ment.
Materials and Methods
Ethics Statement
All animal protocols used in these investigations have been
reviewed and approved by the Dalhousie University Animal Care
committee.
Mouse strains
Generation of AEBP1
2/2 mice was previously described [15].
Age-matched mice were kept on a 12 hr light cycle in the Carleton
Animal Care Facility at Dalhousie University where they were fed
and watered ad libitum. Mice were sacrificed by euthanasia using an
overdose of sodium pentobarbital (Somnitol), and mammary gland
tissues were isolated for histological, whole mount and Western
blot analyses.
Histology and whole mount analysis
For the whole mount preparation of mammary glands, mice
were sacrificed by cervical dislocation at different ages of virgin, at
the appropriate time points during pregnancy, and at parturition
and postpartum. The first inguinal and thoracic glands were
removed and fixed in Carnoy’s solution (ethanol:chloroform:gla-
cial acetic acid, 6:3:1) for 4 hr. Subsequently, the glands were
hydrated, stained with carmine-alum overnight, dehydrated,
cleared in xylene, and mounted with permount. For histological
analysis, mammary gland tissues were fixed in 10% acetate
buffered formalin, paraffin embedded, sectioned at 5 mm and
stained with hematoxylin and eosin. Histologic sections of
mammary glands were examined in each instance.
Immunohistochemistry
Mammary gland sections were deparaffined, rehydrated and
treated in 10 mM sodium citrate (pH 6.0) by boiling for 10
minutes in microwave oven for antigen unmasking. The slides
were treated with 3% hydrogen peroxide to inactivate endogenous
peroxides and then treated with normal rabbit serum. The sections
were treated with anti-p-STAT3 (Cell Signaling Technology,
Beverly, MA, USA), anti-cleaved caspase 3 (Cell Signaling
Technology), or anti-C/EBPd (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The immunoperoxidase staining was performed
using Vectastain ABC kit (Vector Laboratories, Burlingame, CA,
USA) according to the manufacturer’s protocol. The signal was
visualized using DAB peroxidase substrate (Sigma-Aldrich Co.).
Mammary epithelial cell transplantation
Epithelial cell transplants were used to determine if AEBP1
protein is expressed in stromal or epithelial compartments of the
mammary gland. Surgical removal of the parenchyma results in a
gland-free mammary fat pad, referred to as cleared fat pad (CFP),
which is suitable for receiving donor tissue. Briefly, portions of
mammary gland (,2m m
2) were isolated from an adult donor
mouse ($ 6 weeks old) and transplanted into the inguinal (#4)
CFP of a 3 to 4 weeks old female mouse. The transplanted
mammary gland tissue grew to form chimeric secondary
mammary glands consisting of donor-derived epithelial compo-
nent and recipient-derived stroma. Three types of chimeras were
generated: AEBP1
+/+ donor tissue into AEBP1
+/+ recipient mice,
AEBP1
+/+ into AEBP1
2/2 recipient mice, and AEBP1
2/2 donor
tissue into AEBP1
+/+ recipient mice. The thoracic #3 mammary
glands of the recipients served as controls. The mice were allowed
to recover for at least 3 weeks and were subsequently mated with
wild-type males. Following delivery (parturition), the mice were
euthanized and their #3 normal and #4 chimeric mammary
glands were dissected out. Half of each gland was immediately
frozen in liquid N2 for protein analysis while the other half was
prepared for histological analysis. Rat mAb TROMA-1 (Devel-
opmental Studies Hybridoma Bank, University of Iowa) was used
to detect keratin 8; an epithelial marker.
Bone marrow transplantation
Recipient mice at the age of 8–10 weeks were provided with
acidified water with antibiotic (neomycin, 2 mg/ml) for 2 weeks
before BM transplantation procedure. BM cells were collected
from the femurs and tibias of donor mice (6–8 weeks old). Total T
cells were depleted using CD90.2 microbeads (EasySep, StemCell
Technologies (Vancouver, BC, Canada). Recipient mice were
lethally irradiated (900 Rad), and then injected with BM cells
(5.0610
6) through tail vein. Two weeks after BM transplantation,
mice were placed on high-fat diet (HFD) for 20 weeks or mated at
8 weeks post BM transplantation prior to whole mount analysis.
Donor cell engraftment was evaluated by qRT-PCR analysis of
SRY expression in the splenocytes and BM cells.
Protein extraction and Western blot analysis
Mouse mammary gland whole cell protein extracts were
prepared by homogenization in high-salt buffer (500 mM NaCl,
10 mM Tris [PH 7.4], 1% Triton X-100, 2 mM EDTA, 1 mM
DTT, 0.1 mM PMSF, 1 mM Na3VO4, 1 mM sodium molybdate,
and protease inhibitor cocktail). Mammary gland tissue was also
digested in collagenase/dispase (Sigma) solution for 2 hr at 37uC.
Separation of macrophages and epithelial cells were performed
using magnetic EasySep Mouse Monocyte Enrichment Kit and
EasySep Mouse Epithelial Cell Enrichment Kit (EasySep,
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confirmed by flow cytometry. For nuclear protein extraction, the
Active Motif nuclear protein extraction kit (Active Motif) was used
according to the manufacturer’s recommendations. Cell lysis was
performed on ice for 30 min. Clear protein extracts were obtained
by centrifugation for 30 min at 4uC. Protein separation and
immunoblotting, followed by ECL immunodetection system
(Amersham), were performed as previously described [14].
Statistical analysis
Data is expressed as the mean 6 S.D. of the indicated number
of samples. Statistical significance was determined using Student t-
test for un-paired observations. *P,0.05 and **P,0.001 are
considered statistically significant.
Results
AEBP1 is critical in mammary gland development
Homozygous AEBP1
2/2 female mice display defective mam-
mary gland development. When 6–8 weeks old AEBP1
2/2 females
were mated with either AEBP1
+/+ or AEBP1
+/2 males, most of
their pups died within 24 hr, with the entire litter dying by 48 hr.
Of fifteen F2 AEBP1
2/2 mothers analyzed, all were unable to
nurse their pups as determined by the lack of milk in the pup’s
stomachs, despite continued mothering and nurturing by the
mothers and suckling by the pups. Upon fostering with
hemizygous mothers, pups of AEBP1
2/2 mothers thrived. Whole
mount analysis indicated that ductal branching and alveolar
development that accompany pregnancy appear unimpaired in
AEBP1
2/2 mice (Fig. 1A). Although mammary gland tissue of
AEBP1
2/2 females appeared fully developed and filled the fat pad
during late pregnancy, it was unclear whether the alveoli in these
mice differentiated normally with parturition. Hallmarks of
mammary epithelial cell differentiation are the transcriptional
activation of milk protein genes by signal transducer and activator
of transcription (STAT)5 via prolactin (Prl) signaling, followed by
the synthesis and secretion of their corresponding proteins (b-
casein and WAP) [24,25]. As shown in Fig. 1B, b-casein and
WAP proteins are detectable in AEBP1
2/2 mice during late
pregnancy (Pg) and postpartum (PP), suggesting that AEBP1 is an
obligate mediator of normal mammary gland function. Interest-
ingly, both b-casein and WAP levels are significantly increased in
AEBP1
2/2 mammary gland at PP (Fig. 1C). Accumulation of
milk proteins in the mammary gland, which presumably reflects
milk stasis, suggests failed secretory activation in the AEBP1
2/2
mammary gland. Histological change marking the transition from
pregnancy to lactation is the alteration in the size and cellular
distribution of lipid droplets. At mid-pregnancy, small cytoplasmic
lipid droplets (CLDs) can be seen within luminal mammary
epithelial cells. By the end of pregnancy, the CLDs increase
dramatically in size. Following parturition, CLDs are smaller and
localized to the apical surface of the alveolar epithelial cells [5]. It
is interesting to note that in many genetically-engineered mice that
exhibit lactation failure, large CLDs remain after parturition and
can be observed on the first and sometimes even the second day of
lactation [26–32]. Consistently, AEBP1
2/2 mammary glands also
exhibit greatly enlarged alveoli with extended lumina containing
many large CLDs within luminal mammary epithelial cells at 1-
day PP (PP1d, Fig. 1D), suggesting that secretory activation has
not occurred. Subsequently, AEBP1
2/2 mammary glands exhibit
groups of collapsed alveoli with reduced size and number at 2-day
PP (PP2d, Fig. 1D), a precocious involution induced by milk stasis
post-partum. Taken together, accumulation of milk proteins in the
mammary gland, expansion of the luminal space, and the
appearance of large CLDs strongly suggest a failure in secretory
activation in the AEBP1
2/2 mammary glands.
AEBP1 deficiency induces premature involution
It is interesting that an excessive number of exfoliated cells were
detected in AEBP1
2/2 mammary gland tissue (Fig. 2A). A small
number of exfoliated cells were detected as early as day 10 of
pregnancy (panels B, C). The number of exfoliated cells increased
progressively during pregnancy (panels E, F, H, I), then a large
number of the exfoliated cells were detected at 2-day PP (panels K,
L). No such sloughing of cells was observed in wild-type tissues
during this period (panels A, D, G, J). We further examined
possible premature involution in AEBP1
2/2 mammary glands by
comparing STAT3 phosphorylation (p-STAT3) status [33] and
expression of CCAAT/enhancer binding protein (C/EBPd) [34]
and cleaved caspase (c-caspase) 3 [35] as markers of involution.
Premature involution displayed by AEBP1
2/2 mammary glands at
PP is evident based on p-STAT3 induction that usually peaks at
day 1 of weaning (Fig. 2B). Surprisingly, p-STAT3 induction is
evident as early as day 12 of pregnancy and its level is highest at
day 19 of pregnancy in AEBP1
2/2 mice. The amount of p-
STAT3 in AEBP1
2/2 glands is about 5-fold higher than that in
AEBP1
+/+ glands during late pregnancy (Fig. 2C). Immunohis-
tochemical analysis also shows strong p-STAT3 signal in
mammary epithelial cells of AEBP1
2/2 mice at day 19 of
pregnancy (Fig. 2D). Similarly, intense C/EBPd and c-caspase
3 signals are detected in AEBP1
2/2 mammary epithelial cells at
day 19 of pregnancy (Fig. 2D). A number of possible apoptotic
cells expressing c-caspase 3 are detected in the lumen of alveoli
and within the epithelial cell layer of AEBP1
2/2 mammary glands
(Fig. 2D). Circulating prolactin, a lactogenic hormone, levels are
not affected by the disruption of AEBP1 gene in AEBP1
2/2
female/male mice (data not shown). These results suggest that
AEBP1 is critical in signaling the initiation of physiological
apoptosis during mammary gland involution.
AEBP1 expression is modulated during the transition
from pregnancy to lactation
To further substantiate the role of AEBP1 in mammary gland
development, we examined the expression profile of AEBP1 in
mammary gland tissue at various stages during postnatal
development. Based on the mammary gland defect found in
AEBP1
2/2 dams, it is plausible to predict that AEBP1 expression
is regulated during the transition from pregnancy to lactation
when secretory activation occurs [4,5]. Compared to those levels
measured in virgin mice, AEBP1 mRNA expression increases
slightly during late pregnancy (Fig. 3A). Initially during lactation,
AEBP1 mRNA level further increases to about 4-fold above the
virgin level. However, as the animal continues lactating, AEBP1
mRNA level drops. AEBP1 mRNA level also changes when the
animal is weaned as it eventually decreases to the virgin level at
day 2 of weaning. In contrast, ACLP mRNA (Fig. 3A) level was
not significantly changed during mammary gland development.
Compared to its level in virgin mice, AEBP1 protein level also
increases during pregnancy (Fig. 3B). During early lactation (PP1-
3), AEBP1 protein level further increases to about 5-fold higher
than its level in virgin mice. However, as lactation continues,
AEBP1 protein level significantly drops, and it continues to
decrease at weaning (Fig. 3B). Gene expression analysis and
immunoblot analysis demonstrate that expression of AEBP1 is
indeed regulated at the stage of secretory activation during
mammary gland development. Interestingly, there are two forms
of AEBP1 protein during late pregnancy, in which the slow
migrating form of AEBP1 is predominant at the beginning of the
Lactation Defect in AEBP1-Null Mice
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2/2 mice. (A) Whole mounts of mammary glands isolated from AEBP1
+/+ and AEBP1
2/2 mice at
different mammary gland developmental stages. (B) Expression of b-casein and WAP in AEBP1
+/+ and AEBP1
2/2 mammary glands at late pregnancy
(lane 1, Pg18; lanes 2–4, Pg19) and postpartum (lanes 5, 7, 8, PP1d; lane 6, PP2d) was examined using anti-b-casein and anti-WAP antibodies,
respectively. (C) Histograms illustrate densitometric analysis of protein levels shown in (B) where relative protein levels of b-casein and WAP were
determined based on actin expression (n=2–3). (D) Haematoxylin-eosin staining of AEBP1
+/+ and AEBP1
2/2 mammary glands at different mammary
gland developmental stages.
doi:10.1371/journal.pone.0027795.g001
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migrating form of AEBP1 becomes more abundant than the slow
migrating form (Fig. 3C). These results suggest that AEBP1 is
post-translationally regulated during mammary gland develop-
ment. Currently, the mechanism and functional significance of this
modification are unknown. Together, our results suggest that
AEBP1 is critically involved in mammary gland development
during steady-state, pregnancy and postpartum stages. Determi-
nation of the localization of AEBP1 in mammary gland tissue
(stromal vs. epithelial) could provide some hints regarding the
molecular mechanism by which AEBP1 exerts its effects on
mammary gland development.
AEBP1 is a stromal factor and macrophage AEBP1
restoration rescues the mammary gland defect in
AEBP1
2/2 mice
Mammary epithelium grows in association with stroma, in
which they communicate with each other through the extracellular
Figure 2. Ablation of AEBP1 causes progressive sloughing of cells and premature involution during pregnancy and a postpartum.
(A) Haematoxylin-eosin staining of mammary glands during pregnancy (panels A to I) and at two days postpartum (panels J to L) from wild-type (WT)
females (panels A, D, G, J) and AEBP1
2/2 (KO) females (panels B, C, E, F, H, I, K, L). Two different magnifications are shown for the KO samples. Panels H
and K are in same magnification as the WT (panels A, D, G, J). (B) Expression of p-STAT3 protein (relative to total STAT3) in AEBP1
+/+ and AEBP1
2/2
mammary glands was examined using anti-p-STAT3 and anti-STAT3 antibodies. (C) Protein extracts isolated from AEBP1
+/+ (WT: lane 1, Pg16; lane 2,
Pg19) and AEBP1
2/2 (KO: lane 3, Pg16; lane 4, Pg19) mammary glands were subjected to SDS-PAGE and immunoblotting using antibodies against the
indicated proteins. A histogram illustrates densitometric analysis of protein levels where relative protein levels of p-STAT3 were determined based on
total STAT3 (n=3–5). (D) Sections from paraffin-embedded AEBP1
+/+ and AEBP1
2/2 mammary glands at Pg19 were stained with anti-p-STAT3, anti-C/
EBPd and anti-c-caspase 3 antibodies, and counterstained with hematoxylin. Arrows indicate apoptotic epithelial cells that have been shed into the
alveolar lumen.
doi:10.1371/journal.pone.0027795.g002
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2/2
mice could be due to defects in stromal cells and/or a cell-
autonomous defect localized to the epithelial cells. We have
previously shown that AEBP1 is expressed in preadipocytes, but
not in mature adipocytes [10]. AEBP1 is also abundantly
expressed in macrophages [20–22]. Yet, it is difficult to detect
AEBP1 in mammary stroma by immunohistochemistry possibly
due to interference of adipocytes and/or unsuitability of the
antibody to detect the endogenous level. Therefore, we carried out
epithelial cell transplantation experiments [36–38] to determine
the localization of AEBP1 in mammary gland tissue. To separate
stromal from epithelial signals, AEBP1
+/+ or AEBP1
2/2 nullipa-
rous mammary epithelial tissues were transplanted into cleared
mammary fat pads of nulliparous AEBP1
+/+ or AEBP1
2/2
females. After formation of chimeric secondary mammary glands,
which consist of donor-derived epithelium and recipient-derived
stroma, mice were mated with wild-type males. Since AEBP1
2/2
mammary glands display alveolar collapse and epithelial cell
hypoplasia at PP2d, the chimeric mammary glands were examined
at parturition, exhibiting normal lobuloalveolar structure (Fig. 4A).
Western blot analysis of the chimeric mammary gland tissues
demonstrates that mammary epithelial cells do not express AEBP1
(Fig. 4B). AEBP1 expression is detected in the chimeric mammary
gland tissue consisting of AEBP1
+/+ stroma (lanes 4 and 5), but not
AEBP1
2/2 stroma (lane 3). Since AEBP1 expression was analyzed
at PP, it is likely that the slow migrating form of AEBP1 found
exclusively in the PP stage (Fig. 3E) corresponds to AEBP1
protein. Keratin 8, an epithelial marker, is expressed in all
chimeric mammary gland tissues (lanes 3–5), but not in the cleared
mammary fat pads (lanes 1 and 2). These results indicate that
AEBP1 is expressed in the stromal compartment of mammary
gland tissue, suggesting that stromal AEBP1 signals the crosstalk
between mammary stroma and epithelium during mammary
gland development.
Macrophages are an important component of mammary stroma
and they are critical for normal mammary gland development
Figure 3. AEBP1 expression is regulated during mammary gland development. (A) Semi-quantitative RT-PCR analysis of AEBP1 and ACLP
mRNA transcripts in mammary gland at various stages during postnatal development. AEBP1 and ACLP expression was normalized to the mRNA
expression of the small subunit ribosomal protein S24. (B) AEBP1 protein levels at different stages were normalized based on actin expression (n=5).
(C) A representative Western blot analysis of AEBP1 expression at different stages of mammary gland development.
doi:10.1371/journal.pone.0027795.g003
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macrophages in this process are poorly understood. Mammary
macrophages are derived from circulating monocytes, and it is
possible to repopulate mammary gland macrophages by BM
transplantation following c-irradiation [40]. Since AEBP1 is
abundantly expressed in macrophages [20–22], we assessed
whether stromal restoration of AEBP1 expression by transplanting
wild-type BM cells could rescue the mammary gland development
defect in AEBP1
2/2 mice. Remarkably, when the irradiated
chimeric female mice were mated, all of their pups thrived.
Histological analysis at PP2d reveals that mammary glands of the
chimeric mice exhibit enlarged alveoli with extended lumina as in
Figure 4. Stromal expression of AEBP1 regulates mammary gland development. (A) Haematoxylin-eosin staining of chimeric mammary
glands at parturition. (B) Western blot analysis of AEBP1 expression in chimeric mammary glands (n=3–5). Lane 1, CFP of AEBP1
+/+; lane 2, CFP of
AEBP1
2/2; lane 3, AEBP1
+/+ donor epithelial cells grown in CFP of AEBP1
2/2 recipient mouse; lane 4, AEBP1
+/+ donor epithelial cells grown in CFP of
AEBP1
+/+ recipient mouse; lane 5, AEBP1
2/2 donor epithelial cells grown in CFP of AEBP1
+/+ recipient mouse. Actin and epithelial marker keratin 8
were used as controls. (C) Restoration of stromal AEBP1 expression by BM transplantation (AEBP1
2/2/BM-WT chimeric mice) prevents premature
involution displayed by AEBP1
2/2 mice at PP2d as determined by histology following hematoxylin and eosin staining. (D) Western blot analysis of
AEBP1 expression in AEBP1
2/2/BM-WT mammary gland tissues.
doi:10.1371/journal.pone.0027795.g004
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demonstrates that AEBP1 levels are restored in the chimeric
mammary gland tissues (Fig. 4D). These results strongly suggest
that macrophage AEBP1 is a critical stromal factor mediating the
stromal-epithelial crosstalk for functional development of the
mammary gland.
Discussion
To gain insight into the physiological activity of AEBP1,
AEBP1-deficient mice were generated by homologous recombi-
nation. Mice homozygous for a disrupted AEBP1 gene developed
to term but showed defect in growth after birth with no other
macroscopic physical aberrations. AEBP1 gene gives rise to AEBP1
and ACLP mRNAs by alternative splicing [10]. Therefore,
AEBP1-knockout mice, in theory, should be identical to the
ACLP-knockout mice [42], as both disrupt the AEBP1/ACLP gene
and the expression of both proteins. Mice lacking ACLP die
perinatally due to gastroschisis, and only ,6% of ACLP-knockout
mice survive to adulthood [42]. Similarly, very small number of
AEBP1-knockout mice survives to adulthood (,10%). The ratio of
the three classes of mice from heterozygote mating indicated that
the litter size of AEBP1
2/2 mice is about half of the wild-type [15],
which suggests that AEBP1 gene disruption also affects embryonic
development. We have not characterized the embryonic lethality
in the AEBP1-knockout mice. The predominant phenotypes of
surviving adult AEBP1
2/2 mice are the inability of females to
lactate due to defective secretory activation, the infertility of males
possibly due to a fluid reabsorption defect in the efferent ductules
of the reproductive system (unpublished observation), and an
overall smaller size. Layne and coworkers never described the
phenotypes of the surviving adult ACLP-knockout mice, except
the deficiency in wound healing [42]. They concluded that ACLP
is an extracellular matrix protein essential for normal embryonic
development and dermal wound healing. The hypoproliferation
phenotype of ACLP
2/2 fibroblasts observed in their studies is most
likely due to AEBP1 disruption. We have previously shown that
AEBP1 stimulates cell growth and survival and inhibits apoptosis
through positive regulation of MAPK [11] and negative regulation
of PTEN [14,15]. AEBP1 was also shown to modulate MAPK
activation by protecting it from the effects of a MAPK-specific
phosphatase, suggesting that the modulation of MAPK activation
by the protective interaction may constitute a critical role in the
determination between cell growth and differentiation in the
adipogenic lineage [11]. Cell fractionation and immunofluorescent
staining experiments revealed that ACLP is excluded from the
nucleus and cytosol and is localized in the perinuclear space,
indicative of its entry into the secretory pathway [9]. Unlike
ACLP, AEBP1 is detectable in the nucleus and cytosol [8].
Because ACLP is not localized to the cytosol, it is inconceivable
that ACLP can have any effect on MAPK and PTEN functions by
direct protein-protein interaction [14,15], despite the fact that
both AEBP1 and ACLP share the exact regions that mediated
these interactions. AEBP1 also physically interacts with endoge-
nous IkBa in macrophages, which do not express ACLP, and the
interaction is physiologically relevant [20–22].
AEBP1 may be very critical in the functional development of the
mammary gland. In AEBP1
2/2 females, the mammary epithelial
compartment showed aberrant development at late pregnancy and
female mice were unable to nurse their newborn pups, possibly due
to an impaired secretory activation at parturition. The glands may
have failed to switch to a lactation state resulting in a rapid
involution postpartum. It appears that disruption of AEBP1 gene
caused premature mammary gland involution, which is character-
ized by elimination of epithelial cells by apoptosis. AEBP1
expression may be critical in regulating the apoptotic signal in
mammary gland involution. The mammary gland has emerged as a
rich developmental model that depends on epithelial-stromal
interaction. The stroma-derived mediator that signals epithelial cell
proliferation and apoptosis is still elusive. Crosstalk between the
mammary stroma and epithelium is crucial for proper patterning
and functioning of the mammary gland. Disruption of stromal-
epithelial communication can promote uncontrolled proliferation of
mammary epithelial cells and promote mammary tumorigenesis
[43,44].Moreover,theexactcompositionoftheextracellularmatrix
and the nature of the microenvironment surrounding mammary
glands play critical roles in mammary gland morphogenesis,
homeostasis and malignant transformation [45–48]. In this study,
we present experimental findings suggesting a regulatory role for
AEBP1 in the control of mammary gland development, presenting
AEBP1 as a novel developmental factor whose expression is vital for
the maintenance of mammary gland homeostasis. Hence, AEBP1 is
a critical stromal factor implicated in mammary epithelial cell
growth. In addition, AEBP1 may function as an indispensable
mediator of the communication signal between the mammary gland
stromal and epithelial compartments, orchestrating the functional
differentiation and involution of the mammary gland epithelium.
These recent discoveries and developments have changed our
understanding of AEBP1 functions and have offered new insights
into the mechanisms by which endogenous AEBP1 exerts its
physiological effects. The specific lesions resulting from the
absence of ubiquitously expressed AEBP1 gene in only a few cell
types may indicate combinatorial regulatory mechanisms that
utilize shared components leading to unique responses in
mammary gland tissue. Our results open up a new avenue of
research directed towards further understanding of the regulation
of mammary gland development. The availability of AEBP1-
knockout and AEBP1-overexpressing transgenic mice will allow a
more precise clarification of the role of AEBP1 in maintaining
homeostasis in the mammary gland tissue.
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